DeJongh Beth, Birkeland Kade, Brenner Michael
Pharmacy Practice, Concordia University Wisconsin School of Pharmacy, Mequon, WI, 53097, USA.
Am J Cardiovasc Drugs. 2015 Jun;15(3):171-84. doi: 10.1007/s40256-015-0115-6.
Heart failure (HF) affects approximately 5.1 million adults in the USA, with expectations of a rise to nearly 8 million adults by 2030. Patients with HF are at increased risk for morbidity/mortality, and comorbidities can further complicate care for these patients. Diabetes mellitus, chronic pain, arrhythmias, and depression are diagnoses that often coexist with HF. Medications commonly used to treat these comorbidities may induce or worsen HF symptoms, so determining appropriate drug therapy is important. Healthcare providers must understand the relationship between these medications and HF in order to improve prescribing practices to increase patient safety and reduce morbidity and mortality. This manuscript discusses the association between certain medications used to treat the aforementioned diagnoses and their relationship to HF. The purpose of this article is to provide guidance on which pharmacologic options require special consideration, increased monitoring, or complete avoidance in HF patients with diabetes mellitus, chronic pain, arrhythmias, and/or depression.
心力衰竭(HF)在美国影响着约510万成年人,预计到2030年将增至近800万成年人。HF患者的发病/死亡风险增加,合并症会使这些患者的护理更加复杂。糖尿病、慢性疼痛、心律失常和抑郁症是常与HF并存的诊断。常用于治疗这些合并症的药物可能会诱发或加重HF症状,因此确定合适的药物治疗很重要。医疗保健提供者必须了解这些药物与HF之间的关系,以改进处方做法,提高患者安全性,降低发病率和死亡率。本手稿讨论了用于治疗上述诊断的某些药物之间的关联及其与HF的关系。本文的目的是为糖尿病、慢性疼痛、心律失常和/或抑郁症的HF患者提供指导,说明哪些药物选择需要特别考虑、加强监测或完全避免使用。